Pliant Therapeutics, INC 8-K filings

Pliant Therapeutics announced its second quarter 2026 financial results, reporting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095 and a reduced net loss.

Pliant Therapeutics, Inc. announced on July 9, 2026, the expansion of its Board of Directors from seven to nine members, appointing Dr. Robert Iannone and Dr. Flavia Borellini.

Pliant Therapeutics stockholders elected three Class III directors, approved executive compensation, and ratified the appointment of Deloitte & Touche LLP.

Pliant Therapeutics reports Q1 2026 financial results, highlighting progress in its PLN-101095 oncology program and a significant reduction in net loss.

Pliant Therapeutics is repricing all employee stock options to $1.33 and navigating the simultaneous retirement of three board members.

Pliant Therapeutics, Inc. announced the termination of its 2021 at-the-market equity offering agreement and confirmed a new $50 million program with Leerink Partners LLC.

Pliant Therapeutics, Inc. announced the appointment of Minnie Kuo, previously Chief Development Officer, as its new Chief Operating Officer, effective immediately.

Pliant Therapeutics announced that Chief Medical Officer Eric Lefebvre, M.D., will depart the company effective December 15, 2025.

Pliant Therapeutics announced its third quarter 2025 financial results, highlighting progress in its oncology program and a significant reduction in net loss.

Pliant Therapeutics announced the resignation of Hans Hull as Chief Business Officer, effective October 20, 2025.

Pliant Therapeutics, Inc. completed the voluntary prepayment and termination of its $32.4 million loan agreement with Oxford Finance LLC.

Pliant Therapeutics discontinues its lead IPF drug bexotegrast due to an unfavorable risk-benefit profile, while reporting Q2 2025 financial results and advancing its oncology pipeline.

Pliant Therapeutics, Inc. announced that its stockholders approved an amendment to limit officer liability, re-elected Class II directors, and ratified Deloitte & Touche LLP as its independent auditor at the Annual Meeting held on June 5, 2025.

Pliant Therapeutics reports Q1 2025 financial results, provides a corporate update including the strategic realignment of workforce and operations, and anticipates topline data from the BEACON-IPF trial in Q2 2025.

Pliant Therapeutics announces a workforce reduction impacting 45% of employees and the departure of its Chief Legal Officer, expecting $3.6 million in severance costs.

Pliant Therapeutics adopts a stockholder rights agreement to deter hostile takeovers and ensure fair value for all stockholders.

Pliant Therapeutics discontinues its BEACON-IPF Phase 2b trial following a DSMB recommendation due to an imbalance in adverse events, while also reporting Q4 2024 financial results with increased R&D expenses.

Pliant Therapeutics assembles an external expert panel to review unblinded data from its BEACON-IPF Phase 2b trial after a recommendation from the Data Safety Monitoring Board (DSMB) to pause enrollment and dosing.

Pliant Therapeutics has voluntarily paused enrollment and dosing in its BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis following a recommendation from the Data Safety Monitoring Board (DSMB).

Pliant Therapeutics announced its third quarter 2024 financial results and provided a corporate update, highlighting the progress of its BEACON-IPF Phase 2b/3 trial.

Pliant Therapeutics' Board of Directors approved amendments to the company's bylaws, effective September 24, 2024, to align with Delaware law and update procedures for stockholder nominations and proposals.

Pliant Therapeutics reported positive clinical data for bexotegrast in IPF and PSC, along with second quarter 2024 financial results, highlighting increased R&D spending and a net loss.

Pliant Therapeutics reported positive 24-week data from its Phase 2a trial of bexotegrast for primary sclerosing cholangitis (PSC), showing the drug was well-tolerated and demonstrated antifibrotic and anti-cholestatic activity.

Pliant Therapeutics increased its board size, appointed Steve Krognes as a new director and Audit Committee Chair, and held its annual meeting where key proposals were voted on.

Pliant Therapeutics' bexotegrast showed positive results in a Phase 2a trial, reducing lung collagen and improving lung function in patients with idiopathic pulmonary fibrosis.

Pliant Therapeutics announced the implementation of an adaptive Phase 2b/3 trial design for bexotegrast, aiming to significantly accelerate its development, and reported first quarter 2024 financial results.

Pliant Therapeutics has amended its loan agreement to secure up to $150 million in debt financing and announced an accelerated Phase 2b/3 trial for its lead drug candidate, bexotegrast.

Pliant Therapeutics announced positive interim safety and efficacy data from its Phase 2a INTEGRIS-PSC trial and provided a corporate update along with fourth quarter 2023 financial results.

Pliant Therapeutics reports positive 12-week interim results from its Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis, showing the drug was well-tolerated and demonstrated antifibrotic activity.